| |
| Omalizumab for the treatment of severe persistent allergic asthma: a systematic review and economic evaluation |
| Norman G, Faria R, Paton F, Llewellyn A, Fox D, Palmer S, Clifton I, Paton J, Woolacott N, McKenna C |
|
|
| |
Record Status This is an economic evaluation that meets the criteria for inclusion on NHS EED. Bibliographic details Norman G, Faria R, Paton F, Llewellyn A, Fox D, Palmer S, Clifton I, Paton J, Woolacott N, McKenna C. Omalizumab for the treatment of severe persistent allergic asthma: a systematic review and economic evaluation. Health Technology Assessment 2013; 17(52) Indexing Status Subject indexing assigned by NLM MeSH Adolescent; Adrenal Cortex Hormones /therapeutic use; Adrenergic beta-Agonists /therapeutic use; Adult; Age Factors; Anti-Asthmatic Agents /adverse effects /economics /therapeutic use; Antibodies, Anti-Idiotypic /adverse effects /economics /therapeutic use; Antibodies, Monoclonal, Humanized /adverse effects /economics /therapeutic use; Asthma /drug therapy /mortality; Child; Cost-Benefit Analysis; Drug Utilization; Great Britain; Health Services /economics /utilization; Humans; Markov Chains; Models, Economic; Omalizumab; Quality of Life; State Medicine AccessionNumber 22013052646 Date bibliographic record published 27/01/2014 |
| |
|
|
